mek inhibitor rec-4881
mek inhibitor rec-4881: sourced relationships with 1 company · 2 clinical trials tracked.
mek inhibitor rec-4881 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could mek inhibitor rec-4881 → RXRX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) Familial Adenomatous Polyposis; AXIN1 Gene Mutation | Phase 2 |
Clinical Trial Registry Records (2)
A Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation
Primary endpoint: Number of Participants with Dose Limiting Toxicities
A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)
Primary endpoint: Part 1: Maximum (Peak) Plasma Drug Concentration (Cmax) of REC-4881
Frequently asked questions
Which companies have sourced relationships with mek inhibitor rec-4881?
mek inhibitor rec-4881 has dated SEC/FDA relationship records for RECURSION PHARMACEUTICALS, INC..
How many clinical trials involve mek inhibitor rec-4881?
BioSniper tracks 2 clinical trials involving mek inhibitor rec-4881.